{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005180","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.514223+00:00","generated_at":"2026-05-17T17:38:49.639418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction","bullets":["Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).","Cash, equivalents, securities $74.4M as of June 30, 2025; warrant exercise proceeds $35.7M in Q2.","Soquelitinib Phase 1 atopic dermatitis: cohort 3 mean EASI reduction 64.8% at day 28 vs 54.6% for cohorts 1-2 and 34.4% placebo.","50% of evaluable cohort 3 patients had ≥4 point itch reduction (PP-NRS) at day 28; Phase 2 on track by year-end.","Phase 3 PTCL registrational trial enrolling; cash expected to fund operations into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005180","json":"https://secwatch.observer/filing/0001171843-25-005180.json","markdown":"https://secwatch.observer/filing/0001171843-25-005180.md","text":"https://secwatch.observer/filing/0001171843-25-005180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/0001171843-25-005180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/f8k_080725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:38:49.639418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}